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Abstract
Vemurafenib has shown to be very effective in treating late-stage BRAF-mutated
melanoma patients. However, the tumor acquires resistance to this drug over time
and makes the therapeutic treatment given to the patient ineffective. This paper
creates a mathematical model to find optimal dosing schedules under the given
toxicity constraints and calculates the probability of acquiring resistance and the
population of resistant cells, by analysing the birth, death and growth rates of
sensitive and resistant cells.
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Introduction
Patients suffering from late-stage melanoma with the BRAF mutated gene are given
vemurafenib, a drug successful in tackling this mutation. However, the mutation becomes
resistant to the drug during treatment, reducing the drug’s efficacy. Resistance to the
drug arises due to different mechanisms such as overexpressing a cell surface protein
PDGFRB which creates another way for the cancer cells to survive, BRAF survival
pathway gets reactivated due to another oncogene NRAS’s mutation, and stromal cell
secretion of hepatocyte growth factor (HGF). [?] [?] It was found that resistant tumors
showed a continued dependency on BRAF (V 600E)→ MEK → ERK signalling owing
to related BRAF(V600E) expression. [?] An important implication of this is that the
vemurafenib resistant cells depended on the drug to continue to reproduce, which meant
that a discontinuous dosing schedule would hinder the growth of these resistant cells
leading to a hostile environment for the resistant cells.
Quantitatively understanding the manner in which growth and death rates and resis-
tant cell populations are affected by this resistance to the drug, is imperative for creating
better treatment schedules and hence can create a better outcome for the patient. By
using existing drugs but administering the drug in a manner such that the cancer cells do
not become resistant to vemurafenib, the treatment can be extended and hence enhancing
chances of remission. If there already exist resistant cells once the treatment has begun,
we aim to arrest the growth of these resistant cells.
Since mutations conferring resistance can arise as random events during the DNA
replication phase of cell division, the emergence of resistance cells is described well by
stochastic mathematical models wherein resistant cells arise during sensitive cell repli-
cation. Cells were assumed to divide with a fixed and common interdivision time and
each sensitive cell division gives rise to a resistant cell with a certain probability. In this
paper, the model assumes the birth and death rate of each cell population is modeled as
a general-time dependent function. [?] Our model calculates the probability of acquiring
resistance to the drug and the number of resistant cells present in the tumor, which are
essential indicators of success in a dosing schedule. These factors enabled us to create
a model that designs an optimal treatment schedule which minimizes the chance of sen-
sitive cells becoming resistant to the drug, and controls the population of cells already
resistant to the drug.
Extraction of birth, death and growth rates
Figure 1 below depicts HMEX1906 mealnomas dose response to vemurafenib for different
concentrations.
We assumed that the cell populations grow at an exponential rate. Using Figure 1, we
found the growth rates for each concentration. The curve is assumed to be exponentially
increasing until it plateaus at 1200 mm3. Due to its exponential properties we were able
to plot a graph of the logarithm of the tumor volume versus time. This is due to the fact
that the curve is expressed as eλt, where λ is the growth rate of the HMEX1906 cells in
response to the drug, and t is the time elapsed measured in days. Then the logarithm of
such a curve results in λt as a straight line when plotted against time, and the slope of
this straight line would just be the growth rate, λ.
After obtaining the growth rates as described above, we plot in Figure 2 a graph
that contains the growth rates versus the concentration. Figure 3b below represents a
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Figure 1: a) Mice bearing subcutaneous HMEX1906 tumors were dosed with vehicle, 5 mg
kg−1, 15 mg kg−1, 45 mg kg−1 vemurafenib twice daily. [?]
Figure 2: Graph of growth rate vs concentration (mg kg−1) for HMEX 1906 melanoma cells
which are sensitive to the drug.
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Figure 3: b) Parental and vemurafenib-resistant cells were treated with the indicated concen-
trations of vemurafenib and AZD6244 for 72 h [?]
bell shaped curve. It shows that the resistant cells do not proliferate when there is no
drug around and in fact grow faster when the drug is present. We analyzed the data
from this and plotted the growth rates of the parental cells and resistant cells versus the
concentration of the inhibitor in µM . The growth rate was calculated using the following
formula:
λ = (Cell viability %) · λv (1)
where
λv = 0.0911,
which is the growth rate of HMEX1906 cells for the vehicle concentration from Figure 2.
Figure 4 contains plots of the growth rates of parental and resistant cells versus
concentration. Using the data obtained from this figure, we generated functions relating
the growth rate to the concentration for the parental (or sensitive) cells and the resistant
cells. The functions are polynomial expressions, which describe the fitted curves. These
functions form a core part of the mathematical model designed, which is described in
detail in the next section. The growth rate is given by:
λ = λb − λd (2)
where λb, λd are the birth and death rates respectively. We assumed the cell death rate
to be a constant and hence the birth rate is just the sum of the growth rate and death
rate.
Dosing schedules
The functions relating the growth rates and concentration were used in calculating the
probability of acquiring resistance and expected number of resistant cells. To approximate
the size of the resistant cell populations, we first estimated the rate at which resistant cells
are produced from the sensitive cell population. Then, the expected number of resistant











Figure 4: Graph of growth rates of parental and resistant cells versus concentration (µM)
Here, λY is the birth rate of the resistant cell process and µY is the death rate of the
resistant cell process and b(t) is the rate of production of resistant cells from the sensitive
cell population. To find the probability of resistance we assume that there is at least one
resistant cell at a particular time, T . Take N small intervals ∆t which make up the time
interval [0, T ] where ∆t = {t0, t1, ..., tN} and so in general, ti = i∆t. The probability
of resistance of a mutation arising from the sensitive cell process within a given time
interval whose end times are separated only by ∆t is b(ti)∆t, where b(ti) is the rate of
production of resistant cells from the sensitive cell population as explained before. We
assume the population size of a resistant cell clone originating from one resistant cell to
be a single-type birth-death process.
This leads us to finding the probability that a clone originating from a single resistant
cell produced at time t is extinct by time T. Further, the probability that at time T, there
are no resistant cells that have arisen from clones originating in the partition interval
[ti, ti + ∆t], is estimated by summing the probability that no sensitive cell divisions give
rise to a resistant cell in this interval and the probability that a resistant cell is produced
but its clone becomes extinct by time T. Which means that the probability that there are
no resistant cells at time T is then the probability that there are no resistant cells at time
T that have arisen from clones originating in any partition interval. So, the probability
of resistance at time T was calculated using the following formula [?]:
PR(T ) ≡ 1− exp
[∫ T
0
−b(t) + b(t)Pext(t, T )dt
]
(4)
Pext(t, T ) is defined as the probability that a clone originating from a single resistant cell
produced at time t is extinct by time T . Further quantitative details about the above
qualitatively described quantities can be found in the cited reference.
At the start of treatment if there was a small percentage of resistant cells, we consider
the cases of pre-existing resistance. Here, we only consider the case where partial resis-
tance is conferred for otherwise fully resistant cells would be immune to any treatment
administered. Under the assumption of partial resistance, we were able to calculate the
probability of resistance and expected number of resistant cells using equations (3) and
(4). If we consider M as the initial sensitive population size then by including the as-
sumption of pre-existing resistance we have two distinct populations:M(1 − s) sensitive
cells and Ms resistant cells, where s is the initial fractions of resistant cells. The prob-
ability of resistance and expected of resistant cells are calculated in similar fashion and
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Figure 5: Dosing Schedule
Figure 6: Birth rate of sensitive cells versus time(days)
can be explicitly found in the cited reference. [?] Figures 5 through 13 are plots resulting
from the model which takes an initial size of one million sensitive cells in the population.
The plots are analysed in detail in the next section. The discontinuous and continuous
schedules use the same amount of drug and hence a comparison between these sched-
ules reveals the most effective dosing strategy by comparing the values of probability of
resistance, expected number of resistant cells and birth rates over the entire treatment
cycle. The continuous schedule uses the average dose from the discontinuous schedules
but administered without breaks.
Figure 7: Birth rate of resistant cells versus time(days)
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Figure 8: Probaiblity of resistance versus time (s = 0)
Figure 9: Probaiblity of resistance versus time (s = 0.03)
Figure 10: Probaiblity of resistance versus time (s = 0.05)
Figure 11: Expected number of resistant cells versus time (s = 0)
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Figure 12: Expected number of resistant cells versus time (s = 0.03)
Figure 13: Expected number of resistant cells versus time (s = 0.05)
Discussion
The performance of the discontinuous schedules varies as compared to its counterpart
continuous schedules. For example, the birth rate (given by equation (2)) of sensitive
cells against time (Figure 6) shows that after half way through the dosing cycle, only
the discontinuous schedules show the ability to be at 0 or sub-zero rates. Similarly, the
birth rate of resistant cells (Figure 7) after midway through the cycle is very low in the
discontinuous schedules as compared to the continuous schedules.
In the probability of resistance cases, the discontinuous schedules in the case of no
pre-existing resistance (Figure 8) gets a lower probability at the end of the cycle and
the continuous schedule is increasing slowly. What may be causing this behavior is that,
during the first few months, a lot of drug is required to tackle the tumor, and the tumor
doesn’t have the ability to acquire resistance quickly and so the continuous schedule
flourishes in the beginning while the discontinuous schedules lag. More precisely, since
more than 6 months have passed, the continuous schedule creates an environment for the
cancer cells to acquire resistance to the drug which enables the tumor cells to proliferate
over the elapsed time period, and hence the probability of resistance increases gradually
and towards the end, the probability is higher than its counterparts on the discontinuous
schedules. The discontinuous schedules exploit the drug dependency, as seen in Figure
3b, and toward the end of the time period, these schedules display a lower probability of
resistance.
In the pre-existing resistance case of s = 0.03 (Figure 9), up to two-thirds of the
cycle, all schedules have an equal probability of acquiring resistance equal to 1. This
is because if the cell population already has existing resistant cells, it is harder for the
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treatment to exterminate them immediately irrespective of the manner in which the dose
is administered. Only after 130 days the continuous schedule does better than its counter
parts apart from the end where one of the discontinuous schedules catches up after a
steep decline in the last 15 days of the cycle. The s = 0.05 plot (Figure 10) is very similar
in terms of shape to the previous case but is different in terms of the onset of decrease
in probability of resistance in the different schedules.
In the expected number of resistant cells case with no pre-existing resistance (Figure
11), it must be noted that given that there are one million sensitive cells initially and only
less than one resistant cell is expected at most for even the worst performing schedule.
This can be correlated to the probability of resistance graphs, where the chance of ac-
quiring resistance, or producing resistant cells is minimal in the no pre-existing resistance
case. However, the continuous schedule’s curve is increasing only slightly over the entire
cycle but has a lower number of resistant cells expected throughout. In the pre-existing
resistance cases (Figures 12 and 13), the schedules have no distinction between them be-
yond the first half of the cycle, indicating that the drug can eventually tackle the tumor
even if there initially were resistant cells in the population. Initially, when pre-existing
resistant cells exist, a large amount of drug is needed to attempt to neutralize these
resistant cells and so the continuous schedule achieves that but since the discontinuous
schedules give breaks early on, they take almost two months to act effectively.
We notice that the bell shaped curve (Figure 3b) can be exploited towards the end of a
discontinuous schedule since the drug begins to become ineffective in large and continuous
doses at this point. So, breaking the cycle with rest is imperative at this stage. More
investigation could be done to talk about the best practices relating to creating ideal
dosing schedules. For example, one could investigate how long can the tumor tolerate
continuous dosing of large amounts, and then just before the tumor is predicted to acquire
resistance, we switch to a discontinuous schedule which keeps the probability of acquiring
resistance at a low, after researching what type of dosing schedule is optimal for a patient
who has gone through several months of continuous therapy. One could also study a large
range of dose response curves which can be correlated to the key bell shaped resistant
response curve, which could give us further quantitative insight into how the tumor cells
react to being in the presence of a calculated amount of drug.
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